Côd QR

PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study

Abstract Background KRAS (Kirsten rat sarcoma viral oncogene homolog) gene mutation is one of the common driver gene mutations in non-small cell lung cancer (NSCLC) with poor prognosis. There are limited effective treatments for advanced NSCLC patients with KRAS mutation. This study aimed to evaluat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Kunchen Wei, Tiansheng Sun, Xiao Feng, Yang Chen, Qingzhong Liu, Hao Tang
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMC 2025-03-01
Cyfres:BMC Cancer
Pynciau:
Non-small cell lung cancer
KRAS mutation
Immunotherapy
PD-L1
Prognostic markers
Mynediad Ar-lein:https://doi.org/10.1186/s12885-025-13868-9
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg